Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Divestments (2016 - 2017)

Soleno Therapeutics (SLNO) has disclosed Divestments for 2 consecutive years, with $717000.0 as the latest value for Q3 2017.

  • On a quarterly basis, Divestments rose 35750.0% to $717000.0 in Q3 2017 year-over-year; TTM through Dec 2017 was $716000.0, a N/A change, with the full-year FY2018 number at -$172000.0, down 124.02% from a year prior.
  • Divestments was $717000.0 for Q3 2017 at Soleno Therapeutics, up from $3000.0 in the prior quarter.
  • In the past five years, Divestments ranged from a high of $717000.0 in Q3 2017 to a low of -$6885.0 in Q4 2016.